X-Therma pioneers a ground-breaking cold chain platform via a proprietary biopreservation technology, to bring living vaccines, IVF, cell & gene therapies, engineered tissues, and organs to patients off-the-shelf, unleashing the grand potential of all regenerative medicines.

Knowledge from over 4 Billion Years of Nature

Inspired by nature, X-Therma has developed a novel biomimetic molecule, a so-called peptoid, that allows cells and organs to be stored at high subzero temperatures while avoiding possible changes in functionality and viability. The peptoid prevents recrystallization by preventing the process of physical changes resulting from temperature changes.

Chemically defined Safe & Effective Cryopreservation

XT-Thrive® proprietary cryopreservation media is intended for cryopreservation of cell and gene therapies for regenerative medicine applications in ultra-low temperature environments (-70° C to -196° C). XT-Thrive® successfully replaces toxic DMSO solutions in cryopreservation and solves legacy bottlenecks in cell & gene therapy scale-up of cGMP production. Without DMSO and unknown components like serums, it doesn't compromise performance.

Transforming Global Accessibility to Organ Transplantation

X-Therma is building organ preservation and transport technology, that was recently designated as a Breakthrough Device by the FDA. With this technology, X-Therma aims to break down barriers in obtaining life-saving organs and medicine, creating health liberation for all patients in need. The critical extension of the transplantation window by the XT-ViVo® and TimeSeal® Breakthrough Device saves the mass of organs not utilized today (80%) and enables xeno-/engineered-organs.

About X-Therma

X-Therma inc., a venture-backed biotech company is headquartered in Richmond, San Francisco Bay Area, with research centers in Richmond and Berkeley, and has expanded to Austria in Europe. X-Therma has been a selected Industrial User at the Lawrence Berkeley National Laboratory and received over $11M in contracts and grant support from the U.S. Department of Defense, the National Science Foundation, and the California Institute for Regenerative Medicine. The company recently closed an oversubscribed Series A of $13M.



2600 Hilltop Drive; Suite B220

Richmond, CA 94806


Contact: Michael Osborne


X-Therma GmbH
Kaiserjägerstraße 30
A-6020 Innsbruck